PURPOSE: beta-Lapachone (ARQ 501, a formulation of beta-lapachone complexed with hydroxypropyl-beta-cyclodextrin) is a novel anticancer agent with selectivity against prostate cancer cells overexpressing the NAD(P)H:quinone oxidoreductase-1 enzyme. Lack of solubility and an efficient drug delivery strategy limits this compound in clinical applications. In this study, we aimed to develop beta-lapachone-containing polymer implants (millirods) for direct implantation into prostate tumors to test the hypothesis that the combination of a tumor-specific anticancer agent with site-specific release of the agent will lead to significant antitumor efficacy. EXPERIMENTAL DESIGN: Survival assays in vitro were used to test the killing effect of beta-lapachone in different prostate cancer cells. beta-Lapachone release kinetics from millirods was determined in vitro and in vivo. PC-3 prostate tumor xenografts in athymic nude mice were used for antitumor efficacy studies in vivo. RESULTS: beta-Lapachone killed three different prostate cancer cell lines in an NAD(P)H:quinone oxidoreductase-1-dependent manner. Upon incorporation of solid-state inclusion complexes of beta-lapachone with hydroxypropyl-beta-cyclodextrin into poly(D,L-lactide-co-glycolide) millirods, beta-lapachone release kinetics in vivo showed a burst release of approximately 0.5 mg within 12 hours and a subsequently sustained release of the drug ( approximately 0.4 mg/kg/d) comparable with that observed in vitro. Antitumor efficacy studies showed significant tumor growth inhibition by beta-lapachone millirods compared with controls (P < 0.0001; n = 10 per group). Kaplan-Meier survival curves showed that tumor-bearing mice treated with beta-lapachone millirods survived nearly 2-fold longer than controls, without observable systemic toxicity. CONCLUSIONS: Intratumoral delivery of beta-lapachone using polymer millirods showed the promising therapeutic potential for human prostate tumors.
PURPOSE: beta-Lapachone (ARQ 501, a formulation of beta-lapachone complexed with hydroxypropyl-beta-cyclodextrin) is a novel anticancer agent with selectivity against prostate cancer cells overexpressing the NAD(P)H:quinone oxidoreductase-1 enzyme. Lack of solubility and an efficient drug delivery strategy limits this compound in clinical applications. In this study, we aimed to develop beta-lapachone-containing polymer implants (millirods) for direct implantation into prostate tumors to test the hypothesis that the combination of a tumor-specific anticancer agent with site-specific release of the agent will lead to significant antitumor efficacy. EXPERIMENTAL DESIGN: Survival assays in vitro were used to test the killing effect of beta-lapachone in different prostate cancer cells. beta-Lapachone release kinetics from millirods was determined in vitro and in vivo. PC-3 prostate tumor xenografts in athymic nude mice were used for antitumor efficacy studies in vivo. RESULTS: beta-Lapachone killed three different prostate cancer cell lines in an NAD(P)H:quinone oxidoreductase-1-dependent manner. Upon incorporation of solid-state inclusion complexes of beta-lapachone with hydroxypropyl-beta-cyclodextrin into poly(D,L-lactide-co-glycolide) millirods, beta-lapachone release kinetics in vivo showed a burst release of approximately 0.5 mg within 12 hours and a subsequently sustained release of the drug ( approximately 0.4 mg/kg/d) comparable with that observed in vitro. Antitumor efficacy studies showed significant tumor growth inhibition by beta-lapachone millirods compared with controls (P < 0.0001; n = 10 per group). Kaplan-Meier survival curves showed that tumor-bearing mice treated with beta-lapachone millirods survived nearly 2-fold longer than controls, without observable systemic toxicity. CONCLUSIONS: Intratumoral delivery of beta-lapachone using polymer millirods showed the promising therapeutic potential for human prostate tumors.
Authors: V Radjendirane; P Joseph; Y H Lee; S Kimura; A J Klein-Szanto; F J Gonzalez; A K Jaiswal Journal: J Biol Chem Date: 1998-03-27 Impact factor: 5.157
Authors: S Miyamoto; T T Huang; S Wuerzberger-Davis; W G Bornmann; J J Pink; C Tagliarino; T J Kinsella; D A Boothman Journal: Ann N Y Acad Sci Date: 2000 Impact factor: 6.499
Authors: Erik A Bey; Melissa S Bentle; Kathryn E Reinicke; Ying Dong; Chin-Rang Yang; Luc Girard; John D Minna; William G Bornmann; Jinming Gao; David A Boothman Journal: Proc Natl Acad Sci U S A Date: 2007-07-03 Impact factor: 12.779
Authors: S M Planchon; S Wuerzberger; B Frydman; D T Witiak; P Hutson; D R Church; G Wilding; D A Boothman Journal: Cancer Res Date: 1995-09-01 Impact factor: 13.312
Authors: Ashley E Ross; Ashkan Emadi; Luigi Marchionni; Paula J Hurley; Brian W Simons; Edward M Schaeffer; Milena Vuica-Ross Journal: BJU Int Date: 2010-12-22 Impact factor: 5.588
Authors: Long Shan Li; Erik A Bey; Ying Dong; Jieru Meng; Biswanath Patra; Jingsheng Yan; Xian-Jin Xie; Rolf A Brekken; Carlton C Barnett; William G Bornmann; Jinming Gao; David A Boothman Journal: Clin Cancer Res Date: 2011-01-11 Impact factor: 13.801
Authors: Yucel Altundal; Gizem Cifter; Alexandre Detappe; Erno Sajo; Panagiotis Tsiamas; Piotr Zygmanski; Ross Berbeco; Robert A Cormack; Mike Makrigiorgos; Wilfred Ngwa Journal: Phys Med Date: 2014-12-06 Impact factor: 2.685
Authors: Wilfred Ngwa; Rajiv Kumar; Srinivas Sridhar; Houari Korideck; Piotr Zygmanski; Robert A Cormack; Ross Berbeco; G Mike Makrigiorgos Journal: Nanomedicine (Lond) Date: 2014-05 Impact factor: 5.307
Authors: Li Gao; Chuanqi Xie; Yuzhi Du; Xiaodong Wang; Erkang Xuan; Xiuxiu Liu; Yang Zhao; Jianjian Xu; Lan Luo Journal: Drug Deliv Date: 2017-11 Impact factor: 6.419
Authors: Muhammad Shaalan Beg; Xiumei Huang; Molly A Silvers; David E Gerber; Joyce Bolluyt; Venetia Sarode; Farjana Fattah; Ralph J Deberardinis; Matthew E Merritt; Xian-Jin Xie; Richard Leff; Daniel Laheru; David A Boothman Journal: J Surg Oncol Date: 2017-03-27 Impact factor: 2.885